AU2017207862B2 - EGF(A) analogues with fatty acid substituents - Google Patents

EGF(A) analogues with fatty acid substituents Download PDF

Info

Publication number
AU2017207862B2
AU2017207862B2 AU2017207862A AU2017207862A AU2017207862B2 AU 2017207862 B2 AU2017207862 B2 AU 2017207862B2 AU 2017207862 A AU2017207862 A AU 2017207862A AU 2017207862 A AU2017207862 A AU 2017207862A AU 2017207862 B2 AU2017207862 B2 AU 2017207862B2
Authority
AU
Australia
Prior art keywords
hooc
2xado
egf
gglu
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017207862A
Other languages
English (en)
Other versions
AU2017207862A1 (en
Inventor
Jianhe Chen
Patrick William Garibay
János Tibor Kodra
Jesper F. Lau
Lars Linderoth
Salka Elbøl RASMUSSEN
Henning THØGERSEN
Birgit Wieczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2017207862A1 publication Critical patent/AU2017207862A1/en
Application granted granted Critical
Publication of AU2017207862B2 publication Critical patent/AU2017207862B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2017207862A 2016-01-13 2017-01-13 EGF(A) analogues with fatty acid substituents Ceased AU2017207862B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (2)

Publication Number Publication Date
AU2017207862A1 AU2017207862A1 (en) 2018-07-05
AU2017207862B2 true AU2017207862B2 (en) 2020-12-17

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017207862A Ceased AU2017207862B2 (en) 2016-01-13 2017-01-13 EGF(A) analogues with fatty acid substituents

Country Status (26)

Country Link
US (2) US10822385B2 (enExample)
EP (1) EP3402811B1 (enExample)
JP (2) JP6797926B2 (enExample)
KR (1) KR102417487B1 (enExample)
CN (1) CN108473550B (enExample)
AU (1) AU2017207862B2 (enExample)
BR (1) BR112018013820A2 (enExample)
CA (1) CA3010756A1 (enExample)
CL (1) CL2018001868A1 (enExample)
CO (1) CO2018007440A2 (enExample)
DK (1) DK3402811T3 (enExample)
ES (1) ES2916998T3 (enExample)
HR (1) HRP20220720T1 (enExample)
HU (1) HUE058647T2 (enExample)
IL (1) IL260043A (enExample)
LT (1) LT3402811T (enExample)
MX (1) MX2018008681A (enExample)
MY (1) MY195199A (enExample)
PE (1) PE20181376A1 (enExample)
PH (1) PH12018501502A1 (enExample)
PL (1) PL3402811T3 (enExample)
RS (1) RS63298B1 (enExample)
RU (1) RU2747877C2 (enExample)
SA (1) SA518391996B1 (enExample)
SI (1) SI3402811T1 (enExample)
WO (1) WO2017121850A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017121647A1 (en) 2016-01-13 2017-07-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA034898B1 (ru) 2016-01-13 2020-04-03 Грюненталь Гмбх Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
HUE049134T2 (hu) 2016-01-13 2020-08-28 Gruenenthal Gmbh 3-(karboximetil)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán származékok
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами
CN108602777B (zh) 2016-01-13 2022-05-03 格吕伦塔尔有限公司 3-((杂-)芳基)-烷基-8-氨基-2-氧代-1，3-氮杂-螺-[4.5]-癸烷衍生物
JP2020527159A (ja) * 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
JP7434299B2 (ja) * 2018-10-05 2024-02-20 ノヴォ ノルディスク アー／エス インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物
US11633632B2 (en) 2019-03-22 2023-04-25 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
PE20220486A1 (es) 2019-08-07 2022-04-04 Novo Nordisk As Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
CN114641275A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4334235A4 (en) 2021-07-02 2024-11-06 3M Innovative Properties Company AIR LIFT LOCKED WITH A FALL PROTECTION SAFETY DEVICE
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
EP2296694B1 (en) 2008-04-23 2015-08-05 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JPWO2012017774A1 (ja) 2010-08-02 2013-10-03 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
CN104093735B (zh) * 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
WO2013093009A1 (en) * 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
BR112015004734A2 (pt) 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3107937A4 (en) 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
WO2016147162A1 (en) * 2015-03-19 2016-09-22 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
JP2020527159A (ja) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhang, Y. et al., "Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain", Journal of Molecular Biology. 2012, vol. 422, no. 5, pages 685-696. *

Also Published As

Publication number Publication date
CO2018007440A2 (es) 2018-09-28
DK3402811T3 (da) 2022-06-13
US20200407409A1 (en) 2020-12-31
RU2018127882A3 (enExample) 2020-06-19
BR112018013820A2 (pt) 2018-12-11
JP6797926B2 (ja) 2020-12-09
PE20181376A1 (es) 2018-09-05
US20190016768A1 (en) 2019-01-17
LT3402811T (lt) 2022-06-10
EP3402811A1 (en) 2018-11-21
KR20180100177A (ko) 2018-09-07
SA518391996B1 (ar) 2021-07-14
CN108473550A (zh) 2018-08-31
MY195199A (en) 2023-01-11
PH12018501502A1 (en) 2019-03-25
CN108473550B (zh) 2022-11-22
HRP20220720T1 (hr) 2022-09-30
RU2018127882A (ru) 2020-02-13
EP3402811B1 (en) 2022-03-30
HUE058647T2 (hu) 2022-09-28
CA3010756A1 (en) 2017-07-20
WO2017121850A1 (en) 2017-07-20
RU2747877C2 (ru) 2021-05-17
JP2019505521A (ja) 2019-02-28
KR102417487B1 (ko) 2022-07-06
ES2916998T3 (es) 2022-07-06
SI3402811T1 (sl) 2022-06-30
RS63298B1 (sr) 2022-07-29
JP2021035989A (ja) 2021-03-04
AU2017207862A1 (en) 2018-07-05
PL3402811T3 (pl) 2022-07-11
US10822385B2 (en) 2020-11-03
CL2018001868A1 (es) 2018-08-31
IL260043A (en) 2018-07-31
MX2018008681A (es) 2018-09-17

Similar Documents

Publication Publication Date Title
AU2017207862B2 (en) EGF(A) analogues with fatty acid substituents
AU2011231503C1 (en) Novel glucagon analogues
ES2625735T3 (es) Análogos y derivados de GLP-1
US11649269B2 (en) Bifunctional compounds comprising insulin peptides and EGF(A) peptides
AU2021374823B2 (en) Glp-1 prodrugs and uses hereof
AU2004298425A1 (en) Novel GLP-1 analogues linked to albumin-like agents
CN104185639B (zh) Glp-1前体药物
KR20200010353A (ko) Mic-1 화합물 및 그 용도
EP3655426A1 (en) Egf(a) analogues, preparation, formulations and uses thereof
HK1262866B (en) Egf(a) analogues with fatty acid substituents
CA3195872A1 (en) Glp-1 prodrugs and uses hereof
WO2022046739A1 (en) Insulin receptor partial agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired